The trend of multinational pharma companies partnering with academia and small biotechs continues unabated. But given the additional risks inherent in such collaborations, how many of these partnerships will eventually lead to innovative new medicines?
Continue reading “Hidden Risks for Pharma Companies Collaborating with Academia and Small Biotechs”